Opening Bell By Capitalstars : 22 May 2019

CAPITALSTARS NIFTY FUTURES & BANK NIFTY FUTURES OVERVIEWS 22 MAY 2019

CS OPENING BELL:
NIFTY SPOT UP 34@11743
SENSEX SPOT UP 151@39121
BANK NIFTY FUTURES UP 41@30430
HAPPY TRADING!

CS NIFTY FUTURES (MAY) OVERVIEW 
TREND BULLISH
RES 2: 12000
RES 1: 11890
SUP 1: 11520
SUP 2: 11400

CS BANK NIFTY FUTURES (MAY) OVERVIEW
TREND BULLISH 
RES 2: 31000
RES 1: 30750
SUP 1: 30180
SUP 2: 30000

Get more details here:

Call on:9977499927
* Investment & Trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.  

  Intraday stock tips, Financial Advisory Company ,Derivative Free Trial,Stock tips

---

Read More

CORPORATE NEWS BY CAPITALSTARS 21 MAY 2019

Glenmark Pharma gets USFDA nod for Solifenacin Succinate tablets
Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for Solifenacin Succinate Tablets, 5 mg and 10 mg, a generic version of Vesicare Tablets, 5 mg and 10 mg1, of Astellas Pharma US, Inc.
According to CQ VIA sales data for the 12-month period ending March 2019, the Vesicare Tablets, 5 mg and 10 mg market achieved annual sales of approximately $942.7 million.
Glenmark's current portfolio consists of 154 products authorized for distribution in the U.S. marketplace and 58 and spending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

GAIL India to consider bonus issue on May 27
GAIL India, in its press note to the exchanges, informed that the company's board will meet on May 27 to consider bonus issue.
"The board of directors will also consider, the audited financial results for the quarter/ year ended on March 31, 2019, and also to consider the recommendation of final dividend for FY19, if any," the company said in a press note after markets hours to the exchanges on Monday.

Thyrocare Techs founder offers to buy entire companies stake in a unit
Thyrocare Tech, in its press note to the exchanges, informed that Dr A. Velumani, Chainnan, Managing Director & CEO has offered to buy the entire shareholding of the company in Nuclear Healthcare Limited (NHL), the wholly owned subsidiary.
The offer made at the current investment value of Rs194.67cr to ensure that there is no loss to the public shareholders, the company said in a press note to the exchanges on Tuesday.

BHEL commissions two more units of Kaleshwaram project
Bharat Heavy Electricals Limited (BHEL) has successfully commissioned two more pumping units (Units 3&4) of 116 MW each, of the 7x116 MW Kaleshwaram Lift Irrigation Scheme (LIS) Package-6 in Telangana.
BHEL had earlier commissioned units 1&2 of the same project in April 2019. Significantly, the pump for each unit is designed to lift 89.16 cumecs (cubic metres per second) of water by 105.5 metres.

Alembic Pharma receives USFDA approval for Solifenacin Succinate
Alembic Pharma, in its filing to the exchanges on Tuesday, informed that the company has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Solifenacin Succinate Tablets, 5 mg, and 10 mg, reacting to this, shares of the company climbed 1% on the BSE.
The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Vesicare Tablets, 5 mg, and 10 mg, of Astellas Pharma US, Inc. Solifenacin Succinate Tablet is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.

Get more details here:
Call on:9977499927
* Investment & Trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.  

  Intraday stock tips, Financial Advisory Company ,Derivative Free Trial,Stock tips

Read More

Closing Bell By Capitalstars : 21 May 2019

            CS CLOSING BELL:

             NIFTY SPOT DOWN 

                 119 @11709

           SENSEX SPOT DOWN

                  382 @ 38969

    BANK NIFTY FUTURES DOWN 

                  411 @ 30404

           HAPPY TRADING!!!!!!!!!!!

        WWW.CAPITALSTARS.COM 

                +917440449744

   DAILY NIFTY SMART MOVERS 

   

SCRIPTS PRICE PRE. CLOSE CHANGE (%) CHANGE (Rs.) VOLUME (IN 000S)

      Edelweiss Financial

    180.85          170.05    6.35              10.80                        264.89

     Dr. Reddy's Lab

 2655.10        2588.05    2.59            67.05                        86.87

   

   Bharti Infratel

275.00         269.45    2.06             5.55                        84.51

    Bank Of Baroda

125.35        122.85    2.04             2.50                        1703.46

    Divis Lab

1691.15       1660.15    1.87            31.00                        20.56

DAILY NIFTY TOP LAGGARDS

SCRIPTS PRICE PRE. CLOSE CHANGE (%) CHANGE (Rs.) VOLUME (IN 000S)

Tata Motors

176.60         190.00 -7.05           -13.40                    4237.65

Tata Motors - DVR

83.10          88.80 -6.42             -5.70                     980.57

Vodafone Idea

11.85         12.55 -5.58            -0.70                 21096.16

Motherson Sumi Sys

120.55        127.15 -5.19            -6.60                    567.76

BPCL

374.70       392.55 -4.55         -17.85                    470.19

BEST CALL OF THE DAY (FINAL TG )

NIFTY FUTURE 

SELL BANK NIFTY FUT FINAL TGT 

HNI OPTION 

BUY SIEMENS CALL 1200 FINAL TGT 

OPTION PREMIUM 

BUY BPCL PUT 380 FINAL TGT 

OPTION STRATEGY 

BUY JUSTDIAL CALL 660 FINAL TGT 

BLUECHIP OPTION 

BUY JUSTDIAL CALL 680 FINAL TGT 

BLUECHIP FUTURE 

SELL TATA MOTORS FUT FINAL TGT 

CASH PREMIUM 

BUY SIEMENS IN CASH FINAL TGT (20 MAY)

OPTION INTRADAY 

BUY INFY PUT 720 FINAL TGT 

FUTURE INTRADAY 

SELL INFY FUT FINAL TGT 

Get more details here:

  Intraday stock tips, Financial Advisory Company ,Derivative Free Trial,Stock tips
Call on:9977499927
* Investment & Trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.  

Read More